Incentives for organ donation in the United States: Feasible alternative or forthcoming apocalypse?

Current Opinion in Organ Transplantation

Volumn 14, Issue 2, 2009, Pages 140-146

  Hippen, Benjamin ^a   Matas, Arthur ^b  

^a Metrolina Nephrology Associates   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Ethics; Incentives for organs; Organ procurement; Organ supply; Public policy

Indexed keywords

COMPENSATION; DEVELOPING COUNTRY; HEALTH CARE POLICY; INFECTION RISK; INTERPERSONAL COMMUNICATION; KIDNEY DONOR; LIVING DONOR; REVIEW; SOCIAL STATUS; UNITED STATES; COMMERCIAL PHENOMENA; ECONOMICS; ETHICS; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HUMAN; INTERNATIONAL COOPERATION; KIDNEY TRANSPLANTATION; LEGAL ASPECT; MORALITY; MOTIVATION; PATIENT RIGHT; PROGRAM DEVELOPMENT; SOCIOECONOMICS; TRANSPLANTATION; TRAVEL;

COMMERCE; COMPENSATION AND REDRESS; GOVERNMENT REGULATION; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL COOPERATION; KIDNEY TRANSPLANTATION; LIVING DONORS; MORAL OBLIGATIONS; MOTIVATION; PATIENT RIGHTS; PROGRAM DEVELOPMENT; SOCIOECONOMIC FACTORS; TISSUE AND ORGAN PROCUREMENT; TRAVEL; UNITED STATES;

EID: 67651028293     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283295e0d     Document Type: Review

References (60)

1. Cherry, M., Kidney for Sale by Owner: Human Organs, Transplantation and the Market. 2005: Georgetown University Press. 264 p.
2. Hippen BE. In defense of a regulated market in kidneys from living vendors. J Med Philos 2005; 30:593-626.
3. Matas AJ. The case for living kidney sales: rationale, objections and concerns. Am J Transplant 2004; 4:2007-2017.
4. Goodwin M. Black Markets: The Supply and Demand of Body Parts. 2006, Cambridge, UK: Cambridge University Press. 294p.
5. Taylor JS. Stakes and kidneys: why markets in human body parts are morally imperative. Live questions in ethics and moral philosophy. 2005, Aldershot, Hants, England; Burlington, VT: Ashgate Pub. x, 226 p.
6. Gill MB. Sade, Robert M. Paying for Kidneys: The Case against Prohibition. Kennedy Institute of Ethics Journal 2002; 12: 17-45.
7. Gaston RS, Danovitch GM, Epstein RA, et al. Limiting financial disincentives in live organ donation: a rational solution to the kidney shortage. Am J Transplant 2006; 6:2548-2555.
8. USRDS Annual Data Report, 2008. http://www.usrds.org/. [Accessed 29 November 2008]
9. Schold JD, Srinivas TR, Kayler LK, et al. The overlapping risk profile between dialysis patients listed and not listed for renal transplantation. Am J Transplant 2008; 8:58-68.
10. Xue JL, Ma JZ, Louis TA, et al. Forecast of the number of patients with endstage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12:2753-2758.
11. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with endstage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005; 16:3736-3741. (Pubitemid 46211296)
12. Schold JD, Kaplan B, Baliga RS, et al. The broad spectrum of quality in deceased donor kidneys. Am J Transplant 2005; 5 (4 Pt 1):757-765. (Pubitemid 40461285)
13. 2007 OPTN/SRTR Annual Report: Transplant Data 1993-2006. http:// www.ustransplant.org. [Accessed 29 November 2008]
14. Bernat JL, D'Alessandro AM, Port FK, et al. Report of a national conference on donation after cardiac death. Am J Transplant 2006; 6:281-291. (Pubitemid 43382163)
15. Delmonico FL, Morrissey PE, Lipkowitz GS, et al. Donor kidney exchanges. Am J Transplant 2004; 4:1628-1634.
16. BoucekMM, Mashburn C, Dunn SM, et al. Pediatric heart transplantation after declaration of cardiocirculatory death. N Engl J Med 2008; 359:709-714.
17. Risling G. California surgeon faces trial in organ donation case, in Associated Press. November 2, 2008.
18. Casingal V, Glumac E, Tan M, et al. Death on the kidney waiting list: good candidates or not? Am J Transplant 12006; 6:953-956.
19. Hippen B. Preventive measures may not reduce the demand for kidney transplantation. There is reason to suppose this is not the case. Kidney Int 2006; 70:606-607.
20. Hippen B. Innovation and the persistent challenge of collapsing goods. J Value Inq 2007; 40:227-233.
21. Stein R. A Third of Patients on Transplant List are not Eligible, in Washington Post. March 22, 2008.
22. Wolfe RA, McCullough KP, Schaubel DE, et al. Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transplant 2008; 8 (4 Pt 2):997-1011.
23. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Clin J Am Soc Nephrol 2008; 3: 1227-1231.
24. Hippen BE. A modest approach to a new frontier: commentary on Danovitch. Transplantation 2007; 84:464-466. The article discusses the complexity of the relationship between organ trafficking and rates of deceased donation in several countries, with an emphasis on the importance of local, cultural factors in that relationship.
25. Hippen B. Organ Sales and Moral Travails: Lessons from the Living Kidney Vendor Program in Iran. Cato Policy Analysis, No 614, March 20, 2008. Available at http://www.cato.org/pub-display.php?pub-id=9273.
26. Hippen B. Should we pay organ donors: case against paying donors was a litany of errors. BMJ 2008; 337:a596.
27. Mor, E., Transplant Tourism in Israel: Effect on transplant practice and organ donation. Available at http://www.esot.org/Files/Elpat/Content-Files/ XYgDt-Presentation-Mor-text.pdf. [Accessed 29 November 2008]
28. Finkel M. This little kidney went to market. N Y Times Mag 2001; 26-33, 40, 52, 59.
29. Chugh K, Jha V. Commerce in transplantation in Third World countries. Kidney Int 1996; 49:1181-1186. (Pubitemid 26166397)
30. Ivanovski N, Stojkovski L, Cakalaroski K, et al. Renal transplantation from paid, unrelated donors in India: it is not only unethical, it is also medically unsafe. Nephrol Dial Transplant 1997; 12:2028-2029. (Pubitemid 27379491)
31. Lawrence R. Abuse of live related kidney transplantation. Nephrol Dial Transplant 1997; 12:2028. (Pubitemid 27379490)
32. Chugh KS, Jha V. Problems and outcomes of living unrelated donor transplants in the developing countries. Kidney Int 2000; 57 (s74):131-135. (Pubitemid 43309183)
33. Goyal M, Mehta RL, Schneiderman LJ, et al. Economic and health consequences of selling a kidney in India. JAMA 2002; 288:1589-1593.
34. Higgins R, West N, Fletcher S, et al. Kidney transplantation in patients travelling from the UK to India or Pakistan. Nephrol Dial Transplant 2003; 18:851-852. (Pubitemid 36432281)
35. Jha V. Paid transplants in India: the grim reality. Nephrol Dial Transplant 2004; 19:541-543. (Pubitemid 38263110)
36. Sever MS, Kazancioglu R, Yildiz A, et al. Outcome of living unrelated (commercial) renal transplantation. Kidney Int 2001; 60:1477-1483. (Pubitemid 32960042)
37. Naqvi SA, Ali B, Mazhar F, et al. Health status and renal function evaluation of kidney vendors: a report from Pakistan. Am J Transplant 2008; 8:1444-1450. (Pubitemid 351994125)
38. Canales MT, Kasiske BL, Rosenberg ME. Transplant tourism: outcomes of United States residents who undergo kidney transplantation overseas. Transplantation 2006; 82:1658-1661.
39. Gill J, Madhira BR, Gjertson D, et al. Transplant tourism in the United States: a single-center experience. Clin J Am Soc Nephrol 2008; 3:1820-1828.
40. Minutes of the UNOS/OPTN Ethics Committee, May 18, 2006. http://www.unos.org/CommitteeReports/interim-main-EthicsCommittee-6-5-2006-16- 50.pdf.
41. UNOS Board of Directors Statement on Transplant Tourism. http://unos.org/ resources/bioethics.asp?index=12. [Accessed 14 June 2008]
42. Australia and New Zealand Organ Donation Registry 2008 Report. http://www.anzdata.org.au/index-ANZOD.htm. [Accessed 29 November 2008]
43. Tiernan, L., Australia: $50 000 for a kidney? Doctor's proposal highlights desperate health, social crisis, in World Socialist Web Site, May 16, 2008. http://www.wsws.org/articles/2008/may2008/kidn-m16.shtml. [Accessed 29 November 2008]
44. Jha V. End-stage renal care in developing countries: the India experience. Ren Fail 2004; 26:201-208. (Pubitemid 39050658)
45. Danovitch GM. Kidney transplantation from unrelated living donors [Letter]. N Engl J Med 1986; 315:713-714. (Pubitemid 16010943)
46. Curtis JJ. You can be a kidney transplant donor but you can't be a kidney recipient. Am J Transplant 2008; 8:2514-2515.
47. Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transplant 2007; 7:2333-2343. (Pubitemid 47347855)
48. Ramcharan T, Matas AJ. Long-term (20-37 years) follow-up of living kidney donors. Am J Transplant 2002; 2:959-964. (Pubitemid 36330226)
49. Bello AK, Peters J, Rigby J, et al. Socioeconomic status and chronic kidney disease at presentation to a renal service in the United Kingdom. Clin J Am Soc Nephrol 2008; 3:1316-1323.
50. Fored CM, Ejerblad E, Fyzek JP, et al. Socio-economic status and chronic renal failure: a population-based case-control study in Sweden. Nephrol Dial Transplant 2003; 18:82-88. (Pubitemid 36104482)
51. Young EW, Mauger EA, Jiang KH, et al. Socioeconomic status and end-stage renal disease in the United States. Kidney Int 1994; 45:907-911. (Pubitemid 24094507)
52. Gibney EM, King AL, Maluf DG, et al. Living kidney donors requiring transplantation: focus on African Americans. Transplantation 2007; 84:647-649. (Pubitemid 47429047)
53. Hippen, B.E., The Case for Kidney Markets. The New Atlantis, 2006. 14(Fall, 2006): 47-61. http://www.thenewatlantis.com/archive/14/hippen.htm.
54. Matas AJ, Hippen B, Satel S. In defense of a regulated system of compensation for living donation. Curr Opin Organ Transplant 2008; 13:379-385. A review of common objections to a system of regulated compensation for living kidney donors. Includes a comprehensive assessment of public surveys in the United States on the subject, charting the shift in public attitudes from the early 1990s to the present.
55. Bryce CL, Siminoff LA, Ubel PA, et al. Do incentives matter? Providing benefits to families of organ donors. Am J Transplant 2005; 5:2999-3008.
56. Rodrigue JR, Cornell DL, Howard RJ. Attitudes toward financial incentives, donor authorization, and presumed consent among next-of-kin who consented vs. refused organ donation. Transplantation 2006; 81:1249-1256.
57. Jacobs CL, Roman D, Garvey C, et al. Twenty-two nondirected kidney donors: an update on a single center's experience. Am J Transplant 2004; 4:1110-1116. (Pubitemid 38868602)
58. Gilbert JC, Brigham L, Batty DS, et al. The nondirected living donor program: a model for cooperative donation, recovery and allocation of living donor kidneys. Am J Transplant 2005; 5:167-174. (Pubitemid 40095142)
59. Starr DP, Blood: an epic history of medicine and commerce. 1st ed. 1998, New York: Alfred A. Knopf. xv, 441.
60. Matas AJ. Design of a regulated system of compensation for living kidney donors. Clin Transplant 2008; 22:378-384. This paper describes a proposal for how a trial of regulated compensation for living kidney donors might be structured.